Tempus xF
Use
Tempus xF is a 105 gene liquid biopsy circulating tumor DNA (ctDNA) sequencing panel. It is designed to detect oncogenic drivers and resistance mutations, and identifies single nucleotide variants (SNVs), insertions and deletions (INDELs), copy number gains (CNGs) and gene rearrangements. These capabilities help inform precision medicine decisions and optimize treatment strategies.
Special Instructions
Tempus xF can be ordered as a standalone test or in combination with xT CDx. Clinicians can employ longitudinal testing using the xF Liquid Biopsy. An automatic conversion option is available from xT CDx to xF in the event of insufficient tumor tissue. The ordering process can be streamlined through Tempus Hub, paper requisition, or directly from an EHR.
Limitations
The sensitivity of detection for various mutations varies and may not detect mutations present at a low allele fraction. The test's performance in identifying some mutations or resistance mechanisms might be limited by tumor heterogeneity, sampling bias, or clonal hematopoiesis. The results from the liquid biopsy need to be considered in the context of other clinical information.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided